Perspectives thérapeutiques dans la prise en charge des CBNPC de stade III non résécables
Jonathan Khalifa(Inserm), Julien Mazières(Université Toulouse III - Paul Sabatier), Christophe Hennequin(Inserm), H. Léna(Inserm), Carole Massabeau(Institut Claudius Regaud), S. Thureau(Laboratoire d'Informatique, du Traitement de l'Information et des Systèmes), A. Keller(Institut Claudius Regaud), E. Martin(Institut de Cancérologie de l'Ouest)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879